ReviewNano convergence2026
Programmable nanomedicine via bioorthogonal molecular engineering.
Review in Nano convergence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bioorthogonal chemistry provides a versatile strategy for programming nanomedicines beyond static carrier design. It enables post-synthetic installation of functional modules on nanoparticle surfaces, spatiotemporal control of payload activation and release, and higher-order functions arising from nanoparticle aggregation or nanoparticle-cell conjugation in diseased tissues. These capabilities allow nanomedicines to be activated more selectively in space and time and to generate functions that are difficult to achieve with conventional formulations. This review summarizes recent advances in multiscale bioorthogonal engineering for programmable nanomedicines, focusing on surface functionalization, molecular control of drug release, and interparticle or cell-associated assembly, and discusses challenges and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.